

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
22 June 2023 (22.06.2023)



(10) International Publication Number  
**WO 2023/113623 A1**

(51) International Patent Classification:

*A61K 31/498* (2006.01) *A61P 3/10* (2006.01)  
*A61K 38/01* (2006.01) *A61P 25/02* (2006.01)  
*A61K 38/05* (2006.01) *G01N 33/68* (2006.01)

(21) International Application Number:

PCT/NZ2022/050172

(22) International Filing Date:

16 December 2022 (16.12.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

783638 17 December 2021 (17.12.2021) NZ

(71) Applicant: **THE CGP LAB LIMITED** [NZ/NZ]; Rm 102/300 Richmond Road, Grey Lynn, Auckland, 1021 (NZ).

(72) Inventor: **GUAN, Jian**; 801 Scenic Drive, Henderson Valley, Auckland, 0612 (NZ).

(74) Agent: **CREATEIP**; PO Box 21445, Christchurch, 8140 (NZ).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,

(54) Title: ANIMAL, FUNGAL AND MARINE SOURCES OF CGP AND INCREASED CGP CONCENTRATION FOR DISEASE MANAGEMENT AND FOR TREATMENT OF NON-NEUROLOGICAL AND/OR NEUROLOGICAL CONDITIONS

Supplementation  
of cGPMAX™ reduced peripheral  
neuropathy scores in T2DM patients




FIGURE 4

(57) Abstract: Described herein are improvements relating to IGF-1 function analysis, adjustment and its application in disease management of non-neurological and/or neurological conditions. More specifically, methods relating to the clinical application of cyclic glycine-proline (cGP) and/or cGP/IGF-1 molar ratio as the plasma biomarker for prediction of risk and recovery of non-neurological and/or neurological conditions with IGF-1 dysfunction and the use of a cGP containing animal, marine or fungal based material such as concentrate/extract of hydrolysed bovine collagen and marine collagen, mushroom and seaweed along with plant-based cGPMAX™ for the treatment of same. The methods more accurately measure IGF-1 function in vivo indirectly using cGP and cGP/IGF-1 molar ratio along with a means to adjust and normalise cGP and cGP/IGF-1 molar ratio (and hence active IGF-1 concentration), and specific

[Continued on next page]

WO 2023/113623 A1

RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,  
ZA, ZM, ZW.

**(84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

- *with international search report (Art. 21(3))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

---

treatment methods for individuals with a lower or reduction of cGP level relative to a standard set of baseline data. Supplementation of bovine collagen formulated cGPMAX™ effectively improved the sensory function in patients with diabetic neuropathy.